Design Therapeutics (DSGN) EPS (Weighted Average and Diluted) (2021 - 2026)
Design Therapeutics recorded quarterly EPS (Weighted Average and Diluted) of -$0.29 in Q1 2026, down 7.41% quarter-over-quarter from -$0.27 in Q4 2025, and up 6.45% year-over-year from -$0.27 in Q1 2025.
Design Therapeutics' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.29 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 6.45% year-over-year to -$0.29; the TTM figure through Mar 2026 stood at -$1.2 (down 21.21% YoY), while the FY2025 annual figure was -$1.22, down 38.64% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.29 for Q1 2026 at Design Therapeutics, down from -$0.27 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.2 in Q1 2024 to a low of -$0.36 in Q2 2023.
- A 5-year average of -$0.28 and a median of -$0.28 in 2023 frame the typical range for EPS (Weighted Average and Diluted).
- Across the five-year window, EPS (Weighted Average and Diluted) slumped 92.86% in 2022 and jumped 42.86% in 2024, its largest moves.
- Design Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.31 in 2022, then jumped by 32.26% to -$0.21 in 2023, then retreated by 14.29% to -$0.24 in 2024, then fell by 12.5% to -$0.27 in 2025, then decreased by 7.41% to -$0.29 in 2026.
- According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods registered -$0.29, -$0.27, and -$0.3 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Design Therapeutics | 640.15 Mn | 417.32 Mn | - | -0.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.29 |
| Dec 31, 2025 | -0.27 |
| Sep 30, 2025 | -0.30 |
| Jun 30, 2025 | -0.34 |
| Mar 31, 2025 | -0.31 |
| Dec 31, 2024 | -0.24 |
| Sep 30, 2024 | -0.23 |
| Jun 30, 2024 | -0.21 |
| Mar 31, 2024 | -0.20 |
| Dec 31, 2023 | -0.21 |
| Sep 30, 2023 | -0.28 |
| Jun 30, 2023 | -0.36 |
| Mar 31, 2023 | -0.35 |
| Dec 31, 2022 | -0.31 |
| Sep 30, 2022 | -0.32 |
| Jun 30, 2022 | -0.27 |
| Mar 31, 2022 | -0.24 |
| Dec 31, 2021 | -0.20 |
| Sep 30, 2021 | -0.21 |
| Jun 30, 2021 | -0.14 |